title: Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer.
abstract: We used antibody microarrays to probe the associations of multiple serum proteins with pancreatic cancer and to explore the use of combined measurements for sample classification. Serum samples from pancreatic cancer patients (n = 61), patients with benign pancreatic disease (n = 31), and healthy control subjects (n = 50) were probed in replicate experiment sets by two-color, rolling circle amplification on microarrays containing 92 antibodies and control proteins. The antibodies that had reproducibly different binding levels between the patient classes revealed different types of alterations, reflecting inflammation (high C-reactive protein, alpha-1-antitrypsin, and serum amyloid A), immune response (high IgA), leakage of cell breakdown products (low plasma gelsolin), and possibly altered vitamin K usage or glucose regulation (high protein-induced vitamin K antagonist-II). The accuracy of the most significant antibody microarray measurements was confirmed through immunoblot and antigen dilution experiments. A logistic-regression algorithm distinguished the cancer samples from the healthy control samples with a 90% and 93% sensitivity and a 90% and 94% specificity in duplicate experiment sets. The cancer samples were distinguished from the benign disease samples with a 95% and 92% sensitivity and an 88% and 74% specificity in duplicate experiment sets. The classification accuracies were significantly improved over those achieved using individual antibodies. This study furthered the development of antibody microarrays for molecular profiling, provided insights into the nature of serum-protein alterations in pancreatic cancer patients, and showed the potential of combined measurements to improve sample classification accuracy.
authors.affiliation: Van Andel Research Institute, Grand Rapids, Michigan 49503, USA.
authors.forename: Randal
authors.initials: R
authors.lastname: Orchekowski
authors.forename: Darren
authors.initials: D
authors.lastname: Hamelinck
authors.forename: Lin
authors.initials: L
authors.lastname: Li
authors.forename: Ewa
authors.initials: E
authors.lastname: Gliwa
authors.forename: Matt
authors.initials: M
authors.lastname: vanBrocklin
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Marrero
authors.forename: George F
authors.initials: GF
authors.lastname: Vande Woude
authors.forename: Ziding
authors.initials: Z
authors.lastname: Feng
authors.forename: Randall
authors.initials: R
authors.lastname: Brand
authors.forename: Brian B
authors.initials: BB
authors.lastname: Haab
mesh_terms: D000230:Adenocarcinoma / Q000097:blood*; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000737:chemistry / Q000276:immunology; D001798:Blood Proteins / Q000032:analysis* / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood*; D040081:Protein Array Analysis / Q000379:methods*
chemical_list: D000906:Antibodies; D001798:Blood Proteins